Trial reportJournal of addiction medicine
Extended-Release Injectable Naltrexone (XR-NTX) With Intensive Psychosocial Therapy for Amphetamine-Dependent Persons Seeking Treatment: A Placebo-Controlled Trial.
Trial report in Journal of addiction medicine. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 3 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 3 syntheses or guidelines pooled it, 27 citations in OpenAlex.
- Extended-release naltrexone versus oral naltrexone for substance use disorders: A systematic review and meta-analysis.Drug and alcohol dependence · 2025Pooled it
- Pharmacological Treatment of Methamphetamine/Amphetamine Dependence: A Systematic Review.CNS drugs · 2020Pooled it
- Pooled it
- Extended observation of reduced methamphetamine use with combined naltrexone plus bupropion in the ADAPT-2 trial.Addiction (Abingdon, England) · 2024Trial
- The effects of acute oral naltrexone pretreatment on the abuse potential of intranasal methamphetamine, and the relationship between reward/punishment sensitivity and methamphetamine's effects.Behavioural pharmacology · 2022Trial
- Bupropion and Naltrexone in Methamphetamine Use Disorder.The New England journal of medicine · 2021Trial
- Baseline Moderators of Response to Naltrexone and Bupropion in the Treatment of Methamphetamine Use Disorder: An ADAPT-2 Study.Journal of addiction medicineTrial
- Safety of Intravenous Methamphetamine in Patients Taking Mirtazapine: A Two-Site Phase 1b Randomized Controlled Trial.Journal of clinical psychopharmacologyTrial
- Use of Naltrexone for Patients With Stimulant Use Disorder in Malaysia: Protocol for a Retrospective Cohort Study.JMIR research protocols · 2025Article
- Case Report: Unusual oral cavity changes associated with methamphetamine abuse.Frontiers in public health · 2025Article
- Effects of naltrexone on amphetamine choice in rhesus monkeys and rats.Experimental and clinical psychopharmacology · 2023Article
- Methamphetamine Toxicities and Clinical Management.NEJM evidence · 2023 · on this mapReview
- Pharmacotherapy treatment of stimulant use disorder.The mental health clinician · 2021Article
- Immunopharmacotherapeutic advancements in addressing methamphetamine abuse.RSC chemical biology · 2021Review
- History of Alcohol and Opioid Use Impacts on the Long-Term Recovery Trajectories of Methamphetamine-Dependent Patients.Frontiers in psychiatry · 2019Article
- Naltrexone maintenance fails to alter amphetamine effects on intracranial self-stimulation in rats.Experimental and clinical psychopharmacology · 2018Article
- Maintenance on naltrexone+amphetamine decreases cocaine-vs.-food choice in male rhesus monkeys.Drug and alcohol dependence · 2017Article
- Medications for substance use disorders (SUD): emerging approaches.Expert opinion on emerging drugs · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors at 1 institution in 1 country.
Funding
Abstract
objectiveExplore the efficacy of extended-release injectable naltrexone (XR-NTX) for preventing relapse to amphetamine use.
methodClinical trial of 100 amphetamine-dependent, treatment-seeking patients who were randomized to 6 monthly 380 mg doses of XR-NTX or matching placebo before entering intensive outpatient after varying lengths of inpatient treatment in Reykjavik, Iceland. Weekly urine drug tests, retention, and standardized instruments assessed efficacy.
resultsOf 169 approached, 100 were randomized. Although amphetamine dependence was the main reason for seeking treatment, three-quarters or more of participants had 1 or more other substance dependencies. Of 51 randomized to XR-NTX, 20 received 4 or more injections; of 49 assigned to placebo, 26 received 4 or more injections. Of the planned 2400 weekly urine drug tests, 1247 were collected (52%); 4% of these were positive for amphetamine, 8% for benzodiazepine, 7% for marijuana, 1% for cocaine, and 1% for opioid. XR-NTX had no effect on amphetamine-positive tests, retention, or other outcomes. Those providing half or more of their tests attended more weeks of treatment than those providing less than half of their tests (m = 10.76 vs 3.31; t (92) = 5.91, P < 0.0001), and 92 participants provided at least 1 test.
conclusionsAdding XR-NTX to the usual combination of inpatient and intensive outpatient treatment did not reduce amphetamine use. The low prevalence of substance use among collected urine samples, and the association between collected samples and weeks in treatment, was consistent with other studies showing that staying in treatment is associated with better outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.